CXCL12/CXCR4信号通路与非小细胞肺癌的研究进展  

Research progress on CXCL12/CXCR4 pathway and non-small cell lung cancer

作　　者：龚雪巍 郑立敏[1] 盛德乔[1] 

机构地区：[1]三峡大学医学院肿瘤微环境与免疫治疗湖北省重点实验室,宜昌443002

出　　处：《生命的化学》2017年第5期713-718,共6页Chemistry of Life

基　　金：国家自然科学基金面上项目(81172788);湖北省高等学校优秀中青年科技创新团队计划(T201203);肿瘤微环境与免疫治疗湖北省重点实验室(三峡大学)开放基金课题(2015KZL07;2017KZL06)

摘　　要：肺癌是世界上癌症相关死亡的主要原因之一,严重危害了人类健康。近些年来研究发现,趋化因子及其受体与肿瘤的发生发展密切相关。趋化因子CXCL12与其受体CXCR4的结合在非小细胞肺癌的血管生成、侵袭和转移中发挥着重要作用,并有可能作为肺癌治疗的潜在靶点。Lung cancer is one of the leading causes of cancer-related mortality in the world,and it is seriously harm to human health.In recent years,it has been found that chemokines and their receptors are closely related to the occurrence and development of tumors.The binding of chemokine CXCL12 and its receptor CXCR4 play an important role in the angiogenesis,invasion and metastasis of non-small cell lung cancer,and it may be a potential target for the treatment of lung cancer.

关 键 词：CXCL12 CXCR4 非小细胞肺癌 血管生成 侵袭和转移 

分 类 号：R734.2[医药卫生—肿瘤]